Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 705 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Tract Diseases Clear all

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Cholecystitis, Acute, Cholecystitis; Gallstone
Interventions: Stent removal; Procedure
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Cholecystitis
Interventions: 18FDG (an FDA-approved radiopharmaceutical); Drug
Lead sponsor: Alan D. Waxman, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
Interventions: remove Mn from PN if evidence of increased brain Mn on MRI; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 30 Days to 12 Months
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gallbladder Cancer, Liver Cancer, Bile Duct Cancer
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Cholecystitis, Cholelithiasis
Interventions: Laparoscopic cholecystectomy with Xenon light, Laparoscopic cholecystectomy (fluorescent cholangiography); Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Biliary Atresia
Interventions: Corticosteroids, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 6 Months
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 43
States / cities: Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more

Conditions: Cholecystitis
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
Interventions: Blood samples; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,865 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota + 1 more

Conditions: Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions: selumetinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 4 more

Conditions: Cholestasis
Interventions: tauroursodeoxycholic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 20 Days
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Jackson, Mississippi • Cincinnati, Ohio

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: becatecarin; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 3
States / cities: Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism, Sigmoid Colon Diverticulitis, Multinodular Goiter, Thyroid and Parathyroid Surgery
Interventions: Observational study of SWIR imaging device in surgery; Device
Lead sponsor: Cision Vision, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Palo Alto, California • Evanston, Illinois • Glenview, Illinois + 2 more

Conditions: HER2-amplified Biliary Tract Cancers
Interventions: ZW25 (Zanidatamab); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 14
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 11 more

Conditions: Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
Interventions: Endoscopic ultrasound examination; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Gallbladder Diseases
Interventions: Ultrasound; Procedure
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: fluorouracil, gemcitabine hydrochloride, leucovorin calcium; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Biliary Tract Cancer
Interventions: Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more

Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions: A166; Drug
Lead sponsor: Klus Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more

Conditions: Billiary Track Cancer
Interventions: Gemcitabine, Cisplatin, Pembrolizumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Biliary Cirrhosis
Interventions: fenofibrate, placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Miami, Florida • Rochester, Minnesota

Conditions: Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions: Emavusertib, Gemcitabine, Cisplatin, Durvalumab; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions: Seribantumab; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more

Search by objective public record fields.

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Observation vs Early Removal of LAMS in EUS Guided Cholecystoenterostomy

FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis

Brain Manganese Deposition in High Risk Neonates

Quality Of Life in Patients With Malignant Biliary Obstruction

Fluorescent Cholangiography vs White Light for Bile Ducts Identification

A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

Prospective Evaluation of an Endoscopic Ultrasound (EUS)-Based Artificial Intelligence to Assist in the Deployment of Lumen Apposing Metal Stents for Gallbladder Drainage

Extracellular RNA Markers of Liver Disease and Cancer

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer

Shortwave Infrared Surgical Imaging Device Study

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

Emergency Ultrasound of the Gallbladder

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors